<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03700385</url>
  </required_header>
  <id_info>
    <org_study_id>CS0188</org_study_id>
    <nct_id>NCT03700385</nct_id>
  </id_info>
  <brief_title>IMPULSE: A Safety and Feasibility Study of the IOWA Approach Endocardial Ablation System to Treat Atrial Fibrillation</brief_title>
  <official_title>The IMPULSE Study: A Safety and Feasibility Study of the IOWA Approach Endocardial Ablation System to Treat Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Farapulse, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Farapulse, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      IMPULSE is a prospective, single-arm, multi-center, safety and feasibility study evaluating&#xD;
      the IOWA Approach Endocardial Ablation System (FARAPULSE, Inc.) for the treatment of&#xD;
      paroxysmal atrial fibrillation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing catheter ablation for paroxysmal atrial fibrillation will be screened for&#xD;
      enrollment per protocol inclusion and exclusion criteria. Enrolled patients will then undergo&#xD;
      ablation using the IOWA Approach Endocardial Ablation System (FARAPULSE, Inc.). Subjects will&#xD;
      be followed at 7 days, 30 days, 3 months, 6 months and 12 months with a blanking period for&#xD;
      recurrent atrial fibrillation or atrial tachycardia of 3 months following the PEF catheter&#xD;
      ablation procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 19, 2018</start_date>
  <completion_date type="Actual">January 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 21, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients undergoing catheter ablation of paroxysmal atrial fibrillation and meeting all protocol inclusion/exclusion criteria will be treated with the IOWA Approach Endocardial Ablation System.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Safety Endpoint for This Study is the Incidence of Early-onset (Within 7 Days of the PEF Ablation Procedure) Primary Adverse Events (AEs).</measure>
    <time_frame>7 days</time_frame>
    <description>The primary safety endpoint for this study is the incidence of early-onset (within 7 days of the PEF ablation procedure) primary adverse events (AEs).&#xD;
Death&#xD;
Myocardial infarction (MI)&#xD;
Pulmonary vein (PV) stenosis†&#xD;
Diaphragmatic paralysis&#xD;
Atrio-esophageal fistula†&#xD;
Transient Ischemic Attack (TIA)&#xD;
Stroke/Cerebrovascular accident (CVA) Thromboembolism&#xD;
Pericarditis requiring intervention (major)&#xD;
Cardiac Tamponade/Perforation&#xD;
Pneumothorax&#xD;
Vascular Access Complications&#xD;
Pulmonary edema&#xD;
Hospitalization (initial and prolonged)*&#xD;
Heart block&#xD;
Excludes hospitalization (initial &amp; prolonged) solely due to arrhythmia (AF/Atrial Flutter/Atrial Tachycardia) recurrence or due to non-urgent cardioversion (pharmacological or electrical).&#xD;
Pulmonary vein (PV) stenosis or atrio-esophageal fistula that occurs greater than one week (7 days) post-procedure shall be deemed a Primary AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility: Number of Patients With Pulmonary Vein Isolation</measure>
    <time_frame>1 Day (Acute)</time_frame>
    <description>Percentage of subjects achieving pulmonary vein isolation using the IOWA Approach Endocardial Ablation System.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>IOWA Approach Endocardial Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are treated with the IOWA Approach Endocardial Ablation System for paroxysmal atrial fibrillation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IOWA Approach Endocardial Ablation System</intervention_name>
    <description>Endocardial ablation using the IOWA Approach Endocardial Ablation System</description>
    <arm_group_label>IOWA Approach Endocardial Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with PAF who have had at least one AF episode documented within one (1) year&#xD;
             prior to enrollment. Documentation may include ECG, transtelephonic monitor (TTM),&#xD;
             Holter monitor (HM), or telemetry strip.&#xD;
&#xD;
          2. Patients who have failed at least one antiarrhythmic drug (AAD; class I or III, or AV&#xD;
             nodal blocking agents such as beta blockers and calcium channel blockers) as shown by&#xD;
             recurrent symptomatic AF, or intolerance to the AAD or AV nodal blocking agents.&#xD;
&#xD;
          3. Patients who are ≥ 18 and ≤ 70 years of age on the day of enrollment.&#xD;
&#xD;
          4. Antero-posterior left atrial diameter ≤ 5.5 cm as documented by transthoracic&#xD;
             echocardiography (TTE) or computed tomography (CT) within 3 months prior to the&#xD;
             procedure.&#xD;
&#xD;
          5. Subject has no contraindications to intraoperative transesophageal echocardiography;&#xD;
&#xD;
          6. Left ventricular ejection fraction ≥40% as documented by TTE within 12 months prior to&#xD;
             the procedure.&#xD;
&#xD;
          7. Received a standard cardiac work up and is an appropriate candidate for an&#xD;
             investigational procedure as determined by study investigators.&#xD;
&#xD;
          8. Subject is willing and capable of providing Informed Consent to undergo study&#xD;
             procedures and participate in all examinations and follow-up visits and tests&#xD;
             associated with this clinical study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients on amiodarone at any time during the past 3 months prior to enrollment.&#xD;
&#xD;
          2. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac&#xD;
             cause.&#xD;
&#xD;
          3. AF episodes lasting &gt; 7 days.&#xD;
&#xD;
          4. Previous ablation for AF.&#xD;
&#xD;
          5. Patient has a prosthetic heart valve.&#xD;
&#xD;
          6. Patient has a left atrial appendage device&#xD;
&#xD;
          7. Prior history of pericarditis or pericarditis within 3 months based on the TTE&#xD;
             examination.&#xD;
&#xD;
          8. Subject is a woman of child bearing age&#xD;
&#xD;
          9. Prior history of rheumatic fever.&#xD;
&#xD;
         10. Prior history of medical procedure involving instrumentation of the left atrium&#xD;
             (previous ablation, Atrial septal defect ASD closure, left atrial appendage occlusion)&#xD;
&#xD;
         11. History of severe chronic gastrointestinal problems involving the esophagus, stomach&#xD;
             and/or untreated acid reflux&#xD;
&#xD;
         12. History of abnormal bleeding and/or clotting disorder.&#xD;
&#xD;
         13. Active malignancy or history of treated cancer within 24 months of enrollment.&#xD;
&#xD;
         14. Clinically significant infection or sepsis.&#xD;
&#xD;
         15. History of stroke or TIA within prior 6 months&#xD;
&#xD;
         16. New York heart Association (NYHA) class IIIb or IV congestive heart failure and/or any&#xD;
             heart failure hospitalization within 3 months prior to enrollment.&#xD;
&#xD;
         17. Body mass index &gt; 35.&#xD;
&#xD;
         18. Estimate glomerular filtration rate (eGFR) &lt; 60 mL/min/1.73 m2 or has ever received&#xD;
             dialysis.&#xD;
&#xD;
         19. History of untreated and serious hypotension, bradycardia or chronotropic&#xD;
             incompetence.&#xD;
&#xD;
         20. Any of the following within 3 months of enrollment:&#xD;
&#xD;
               -  Major surgery except for the index procedure&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  Percutaneous coronary intervention (e.g., CABG or PTCA)&#xD;
&#xD;
               -  Sudden cardiac death event&#xD;
&#xD;
               -  Left atrial thrombus that has not resolved as shown by TEE or CT&#xD;
&#xD;
               -  Implant of pacemaker, ICD or CRT.&#xD;
&#xD;
         21. Solid organ or hematologic transplant, or currently being evaluated for an organ&#xD;
             transplant&#xD;
&#xD;
         22. History of pulmonary hypertension with Pulmonary systolic artery pressure &gt;50 mm Hg,&#xD;
             severe Chronic Obstructive Pulmonary Disease or restrictive lung disease.&#xD;
&#xD;
         23. Patients with any other significant uncontrolled or unstable medical condition (such&#xD;
             as uncontrolled brady-arrhythmias, ventricular arrhythmias, hyperthyroidism or&#xD;
             significant coagulation disorder).&#xD;
&#xD;
         24. Life expectancy less than one year.&#xD;
&#xD;
         25. Clinically significant psychological condition that in the physician's opinion would&#xD;
             prohibit the subject's ability to meet the protocol requirements.&#xD;
&#xD;
         26. History of blood clotting or bleeding abnormalities.&#xD;
&#xD;
         27. Contraindication to anticoagulation (i.e., heparin, dabigatran, Vitamin K Antagonists&#xD;
             such as warfarin).&#xD;
&#xD;
         28. Enrolled in another cardiac clinical study that would interfere with this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petr Neuzil, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemocnice Na Homolce</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nemocnice Na Homolce</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>October 4, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <results_first_submitted>August 15, 2020</results_first_submitted>
  <results_first_submitted_qc>September 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 23, 2020</results_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT03700385/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 40 subjects consented and were treated.</recruitment_details>
      <pre_assignment_details>A total of 40 patients were enrolled (signed informed consent) and 40 subjects were treated at two (2) sites in Europe.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>IOWA Approach Endocardial Ablation</title>
          <description>Subjects who are treated with the IOWA Approach Endocardial Ablation System for paroxysmal atrial fibrillation.&#xD;
IOWA Approach Endocardial Ablation System: Endocardial ablation using the IOWA Approach Endocardial Ablation System</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IOWA Approach Endocardial Ablation</title>
          <description>Subjects who are treated with the IOWA Approach Endocardial Ablation System for paroxysmal atrial fibrillation.&#xD;
IOWA Approach Endocardial Ablation System: Endocardial ablation using the IOWA Approach Endocardial Ablation System</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.2" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Czechia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Safety Endpoint for This Study is the Incidence of Early-onset (Within 7 Days of the PEF Ablation Procedure) Primary Adverse Events (AEs).</title>
        <description>The primary safety endpoint for this study is the incidence of early-onset (within 7 days of the PEF ablation procedure) primary adverse events (AEs).&#xD;
Death&#xD;
Myocardial infarction (MI)&#xD;
Pulmonary vein (PV) stenosis†&#xD;
Diaphragmatic paralysis&#xD;
Atrio-esophageal fistula†&#xD;
Transient Ischemic Attack (TIA)&#xD;
Stroke/Cerebrovascular accident (CVA) Thromboembolism&#xD;
Pericarditis requiring intervention (major)&#xD;
Cardiac Tamponade/Perforation&#xD;
Pneumothorax&#xD;
Vascular Access Complications&#xD;
Pulmonary edema&#xD;
Hospitalization (initial and prolonged)*&#xD;
Heart block&#xD;
Excludes hospitalization (initial &amp; prolonged) solely due to arrhythmia (AF/Atrial Flutter/Atrial Tachycardia) recurrence or due to non-urgent cardioversion (pharmacological or electrical).&#xD;
Pulmonary vein (PV) stenosis or atrio-esophageal fistula that occurs greater than one week (7 days) post-procedure shall be deemed a Primary AE.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IOWA Approach Endocardial Ablation</title>
            <description>Subjects who are treated with the IOWA Approach Endocardial Ablation System for paroxysmal atrial fibrillation.&#xD;
IOWA Approach Endocardial Ablation System: Endocardial ablation using the IOWA Approach Endocardial Ablation System</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Safety Endpoint for This Study is the Incidence of Early-onset (Within 7 Days of the PEF Ablation Procedure) Primary Adverse Events (AEs).</title>
          <description>The primary safety endpoint for this study is the incidence of early-onset (within 7 days of the PEF ablation procedure) primary adverse events (AEs).&#xD;
Death&#xD;
Myocardial infarction (MI)&#xD;
Pulmonary vein (PV) stenosis†&#xD;
Diaphragmatic paralysis&#xD;
Atrio-esophageal fistula†&#xD;
Transient Ischemic Attack (TIA)&#xD;
Stroke/Cerebrovascular accident (CVA) Thromboembolism&#xD;
Pericarditis requiring intervention (major)&#xD;
Cardiac Tamponade/Perforation&#xD;
Pneumothorax&#xD;
Vascular Access Complications&#xD;
Pulmonary edema&#xD;
Hospitalization (initial and prolonged)*&#xD;
Heart block&#xD;
Excludes hospitalization (initial &amp; prolonged) solely due to arrhythmia (AF/Atrial Flutter/Atrial Tachycardia) recurrence or due to non-urgent cardioversion (pharmacological or electrical).&#xD;
Pulmonary vein (PV) stenosis or atrio-esophageal fistula that occurs greater than one week (7 days) post-procedure shall be deemed a Primary AE.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Feasibility: Number of Patients With Pulmonary Vein Isolation</title>
        <description>Percentage of subjects achieving pulmonary vein isolation using the IOWA Approach Endocardial Ablation System.</description>
        <time_frame>1 Day (Acute)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IOWA Approach Endocardial Ablation</title>
            <description>Subjects who are treated with the IOWA Approach Endocardial Ablation System for paroxysmal atrial fibrillation.&#xD;
IOWA Approach Endocardial Ablation System: Endocardial ablation using the IOWA Approach Endocardial Ablation System</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility: Number of Patients With Pulmonary Vein Isolation</title>
          <description>Percentage of subjects achieving pulmonary vein isolation using the IOWA Approach Endocardial Ablation System.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>IOWA Approach Endocardial Ablation</title>
          <description>Subjects who are treated with the IOWA Approach Endocardial Ablation System for paroxysmal atrial fibrillation.&#xD;
IOWA Approach Endocardial Ablation System: Endocardial ablation using the IOWA Approach Endocardial Ablation System</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Atrial Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Cardiac Tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher (Kit) Schneider Sr. Director of Clinical &amp; Pre-Clinical Engineering</name_or_title>
      <organization>FARAPULSE, Inc.</organization>
      <phone>617-686-7661</phone>
      <email>kschneider@farapulse.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

